2017 Taiwan Biotechnology Delegation to Belgium, Netherlands, Switzerland & Germany

October 28th - November 8th, 2017

Co-organized by:

中華民國國際經濟合作協會
Chinese International Economic Cooperation Association

Chinese International Economic Cooperation Association

Bio Taiwan
台灣生物產業發展協會

Taiwan Bio Industry Organization

Members of Delegation

No.	Name & Title	Organization/Type	Sub-sector	Page
1	**Dr. Johnsee LEE** Chairman	**Taiwan Bio Industry Organization** Cluster	General	4
2	**Dr. Bor-fuei (Apo) HUANG** Secretary General			
3	**Ms. Shu-fu (Amy) KO** Project manager	**Development Center for Biotechnology** Research Institute	Pharma, Diagnostics, Device & Service	5
4	**Ms. Shu-tzu YEH** Project manager			
5	**Dr. Tse-wen CHANG** President & CEO	**Immunwork, Inc.** Company	Pharma	7
6	**Mr. Yao-hsien WANG** CEO	**Southern Medical Science LTD** Company	Device	8
7	**Ms. Kuei-hwa (Sybil) YANG** Chairman & CEO	**Phalanx Biotech Group** Company	Device, Service & IVD	9
8	**Ms. Shang-chi (Sandy) LIN** Assistant vice president			
9	**Dr. Chun-mao LIN** Professor	**Taipei Medical University** Academic & Research Institute	Pharma	10
10	**Dr. Chiao-Ying LIN** Assistant Professor			
11	**Dr. Tse-hua TAN** Director	**Immunology Research Center, National Health Research Institutes** Research Institute	Pharma & Diagnostics	12
12	**Mr. Chris TSAI** Chairman	**BIONET Corp.** Company	Stem Cell, Genetic Testing, Informatics, Precision Medicine	13
13	**Ms. Tiffany WANG** Sales and Marketing Specialist	**Quark Biosciences** Company	Diagnostics, Device, Service	14
14	**Dr. Ae-Jun WANG** Chairman	**Andros Pharmaceuticals Co., Ltd.** Company	Pharma	15
15	**Ching-Leou TENG** Chairperson	**PharmaEssentia Corp**. Company	Pharma	16
	Ko-Chung LIN CEO			

16	**Ken HWANG** Division Director	**Industrial Technology Research Institute** Company	Pharma	17
17	**Winters Fu** Director, Business Development Dept.	**Trust Bio-sonics, Inc.** Company	Pharma	18
18	**Dr. Stanley Chang** CEO	**Medigen Biotechnology Corporation** Company	Pharma	19
19	**Vera Liu** Manager	**Personal Genomics** Company	Biotech	20
20	**Angus Wu** Associate Director	**ACT Genomics** Company	Diagnostics	21
21	**Frank Lin** Vice President	**General Biologicals Corp. (GBC)** Company	Diagnostics	22
22	**George Yeh** CEO	**TLC** Company	Biotech	23
23	**Johnson Yu** Project Manager	**PharmaEngine, Inc.** Company	Biotech	24
24	**Amy Huang** CEO	**OBI Pharma,Inc..** Company	Biotech	25

Taiwan Bio Industry Organization (TBIO)

Sub-sectors: General

Dr. Johnsee LEE, Chairman
Dr. Bor-fuei (Apo) HUANG, Secretary General

Address: 7F.-1, No. 3-2, Park St., Nangang Dist., Taipei 115, Taiwan
Email: biotaiwan@gmail.com
Tel: 886-2-2655 8692
Website:
http://taiwanbio.org.tw/en/
www.bio-taiwan.com

Introduction

Taiwan Bio Industry Organization (TBIO) was established in 1989, is the largest and the most influential biotechnology organization in Taiwan. TBIO represents over 300 members ranging from private companies and academic institutes to government bodies involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology. We are a strong arm to foster the development of biotechnology in Taiwan. Our mission is to provide advocacy, business development, international partnership and communication service for our members.

TBIO organize the annual BioTaiwan conferences and exhibition, the largest gathering of biotechnology industry in Taiwan. BioTaiwan 2018, the 16th annual biotech festival of events is taking place July 18-22 in Taipei, Taiwan.

Interests

Cooperate with local biotech clusters and associations in promoting international business cooperation between Taiwan and foreign biotech sectors.

Development Center for Biotechnology (DCB)

Sub-sectors: Pharma, Diagnostics, Device & Service

Ms. Shu-fu (Amy) KO, Project manager
Tel: 886-2-2395 7977 ext. 30
Email: nijemegenko@gmail.com or nijmegenko@dcb.org.tw
Ms. Shu-tzu YEH, Project manager
Email: szyeh914@gmail.com or szyeh@dcb.org.tw

Address: No. 101, Lane 169, Kang-ning Street, Xizhi Dist., New Taipei City 221, Taiwan
Tel: 886-2-2695 6933
Website: http://www.dcb.org.tw/home.php

Introduction

The Development Center for Biotechnology (DCB) is a not-for-profit organization founded in 1984. DCB's mission is to facilitate the development of Taiwan's biotechnology industry by building the infrastructures, developing key biotechnologies, and training and recruiting professional workforces, in coordination with industrial, governmental, academic, and research institutions.

DCB positions itself as a "Preclinical Value-Adding R&D and Integrated Service Center for Biopharmaceuticals" to provide integrated services ranging from R&D to business development. This role is to be fulfilled by devoting concerted efforts on preclinical developments of protein, small-molecule and botanical drug leads.

DCB also dedicates itself in protecting IP and promoting R&D products resulted both from Taiwan's academia and industrial programs, fostering the transfer of domestic upstream R&D products to the industry. DCB plays the role as a "second runner" of value-adding and incubation in the value chain of Taiwan's biotech-pharma industry. It continues the new drug discovery results of the first-runner research and academic institutions and introduces innovative technology or lead compounds from foreign entities. Via pre-clinical development and value-adding, those achievements are to be transferred to the third-runner biotech-pharma companies where the R&D results are directed to commercialization. In this regard, DCB launched its Drug Commercialization Center program this year, dedicated to technology commercialization. DCB is actively exploring new opportunities of technology transfer and international collaboration.

Interests

- Technology transfer: license in and license out
- Co-development or other partnership for medical device or pharmaceutical cases from academia and industry in Taiwan
- Out Sourcing for the product or CRO service: (1) eye-related case (treatment for AMD, DME, dry-eye); (2) cases in infectious disease: biologics (vaccine and antibody) & IVD for Dengue virus detection , rapid screening , server group screening, and DHF & DHS treatment; (3) Cancers; (4) Immuno-oncology; (5) Neurological Diseases; (6) Cardiovascular & Metabolic Diseases.

Immunwork, Inc.

Sub-sector: Pharma

Dr. Tse-wen CHANG, President & CEO
Tel: 886-926 618 000
Email: tsewen.chang@immunwork.com

Address: Nangang District, Taipei City 115, Taiwan
Website:
http://www.immunwork.com/

Introduction

Immunwork Inc. was founded in 2014. It focuses on the research, development, and commercialization of a class of new drugs, which are created based on its proprietary technology platform, for treating multiple types of cancer, a number of severe indications in autoimmune, osteoporosis, infectious, and central nervous system diseases, pathological blood clots, rejection reaction in organ transplantation, and other selected severe clinical conditions.

Immunwork's technology platform enables the Developing a series of new pharmaceuticals with both targeting (T) and effector (E) functions, based on a novel drug design platform for producing antibody drug conjugates and bispecific antibodies, for applications in oncology, autoimmune, CNS, infectious diseases, and blood clotting treatments, etc. Its T-E pharmaceuticals are based on a "multi-arm linkers" novel technology and potentially have better efficacy and safety profiles than existing drugs with only effector functions. We have created a series of new drugs and can potentially make many existing drugs better.

Interests

- New project co-development and R&D cooperation
- Partners interested in improved ADCs and bispecific antibodies for oncological applications; anti-TNFα with collagen VII targeting for various severe skin inflammatory diseases; anti-amyloid β with transferrin receptor targeting for treating Alzheimer disease; human tissue plasminogen activator with fibrin targeting for treating blood clots in strokes and heart attacks; various other products
- Targeted companies in Belgium: UCB, Janssen Pharmaceutica

Southern Medical Science LTD

Sub-sector: Device

Address: No. 139, Chenggong Rd., Qiaotou Dist., Kaohsiung City 825, Taiwan

Mr. Yao-hsien WANG, CEO
Email: pharwang@gmail.com

Introduction

Founded in May 2017, Southern Medical Science is a young and energetic medical device designer and manufacturer. Its core product, a novel Adipose Derive Stem Cells (ADSCs)-isolation equipment, can provide good quality autologous ADSCs for stem cell based regeneration medicine. It can provide ADSCs within 1.5 hour during the surgical operation.

The device's user-friendly interface allows it to be easily operated. Each device contains two major parts: the functional module and a disposable kit, which can be replaced for each user.

Interests

Looking for market developer or distributor in Europe for the vet medical care market

Phalanx Biotech Group

Sub-sectors: Device, Service, IVD

Address: No.6, Keji 5th Rd., East Dist., HsinChu City 300, Taiwan
Tel: 886-3-578 1168
Website: https://www.phalanxbiotech.com/

Ms. Kuei-hwa (Sybil) YANG, Chairman & CEO
Ms. Shang-chi (Sandy) LIN, Assistant vice president

Introduction

PhalanxBio Inc, is a subsidiary of the parent company, Phalanx Biotech Group (Taiwan) which was established in 2002, as an offshoot of the prestigious Industrial Technology Research Institute of Taiwan (ITRI). In 2013, PhalanxBio Inc moved to San Diego, CA to be part of the thriving local biotech community and to provide comprehensive genomic services and bioinformatics to the life science research community.

Phalanx Biotech Group is the original manufacturer for the OneArray® brand of microarrays and has developed a stellar reputation (with almost 400 publications) in the research use of its own microarray line. The Phalanx service lab is known globally for its delivery of high quality data. Phalanx is able to provide custom printing solutions and probe design to global customers.

On the clinical front, Phalanx Biotech Group has pioneered its own CytoOneArray microarray chip, for detecting developmental delays. This product and complementary service is only available in the U.S. for research purposes and not yet approved for clinical diagnostics. However, its clinical use is being implemented internationally.

Phalanx Biotech's capabilities include microarray service, miRNA service, qRT-PCR, custom printing, Next Generation Sequencing (NGS) and an entire suite of complementary bioinformatics analyses.

Interests

- Looking for Co-development or other partnership for high throughput disease screening
- Sourcing for genetic automation product or genetic service customers
- Targeted companies in Germany: LifeCodexx AG

Taipei Medical University (TMU)

Sub-sectors: Pharma

Dr. Chun-mao LIN, Professor (Department of Biochemistry and Molecular Cell Biology) & Dean (Office of Business Development)
Email: cmlin@tmu.edu.tw
Dr. Chiao-Ying LIN, Assistant Professor

Address: No. 250, Wuxing St., Xinyi Dist., Taipei City 110, Taiwan
Tel: 886-2-2736 1661
Website:http://www.tmu.edu.tw/english/main.php

Introduction

Taipei Medical University (TMU) is into a world-class university with ten colleges, 6,000 students per year, three hospitals and more than 3,000 beds for clinical trial, and more than 40,000 alumni around the world, serving the society and humankind and also cultivating the future talents for the nation.TMU has been strongly promoting internationalization efforts with a total of 200 partner institutions around the world, conducting international research collaboration with US institutions such as Case Western Reserve University, Johns Hopkins University, University of Chicago, University of Texas Health Science Center at Houston, Stanford University, Yale University and US National Institutes of Health to name a few. Also, TMU has also signed 18 dual-degree program partnerships with the Université du Droit et de la Santé Lille 2 in France, Hokkaido University in Japan, and others, in an effort to provide TMU students with opportunities to further their education abroad.

TMU is looking for research partners for the following topics:

(1) Biomarker for endometrium and ovarian cancer: DNA methylation biomarker has been found for cancer detection. It can be used for developing a simple, reliable, and cost-effective screening tool for endometrial and ovarian cancer. It is more sensitivity and specificity than vaginal ultrasound and CA125 blood screening. At present the relevant patent has applied for PCT.

(2) Fast and Low Cost Personalized Cancer Drug Evaluation Platform: The technique uses unique microtubule array membrane (MTAM) technology to produce novel microtubule array membrane that can be implanted in animals. It can be applied to (A) Rapid drug screening test, providing reliable animal model for pharmaceutical companies to develop anticancer drug screening; (B) Individualized medical treatment of patients with rapid drug screening services to replace the current "patient-derived tumor xenograft (PDTX) model" for in vivo evaluation of anti-cancer drug activity, significantly shorten the optimal drug screening time, to provide clinicians the reference for the cancer drug selection. To achieve the purpose of patients early optimization treatment to improve medical results and reduce treatment costs.

Interests

Technology transfer (license out) & Co-development or other partnership on biomarker for endometrium and ovarian cancer & fast and Low cost personalized cancer drug evaluation platform

National Health Research Institutes (NHRI)

Sub-sectors: Pharma & Diagnostics

Dr. Tse-hua TAN, Director and Distinguished Investigator, Immunology Research Center
Email: ttan@nhri.org.tw

Address:
No.35, Keyan Rd.,Zhunan Township,
Miaoli County 350, Taiwan
Tel: 886-37-246 166
Website:
http://english.nhri.org.tw/NHRI_WEB/nhriw001Action.do

Introduction

The National Health Research Institutes (NHRI) is a non-profit foundation established in 1995. As an autonomous research organization under the supervision of the Ministry of Health, the NHRI is dedicated to the enhancement of medical research and the improvement of health care in this country.

Scientists at the NHRI conduct mission-oriented medical research and investigate many aspects of the basic biomedical sciences, as well as specific diseases. These range from the common problems such as aging, cancer, infectious diseases, mental disorders, occupational diseases, to health policy. It is our hope that the knowledge, experience, and facilities at the NHRI will become important resources to the whole nation in understanding, preventing, and curing diseases.

Under NHRI, the Immunology Research Center focuses its research on the following topics:

(1) MAP4K3/GLK: The kinase MAP4K3 is a biomarker and therapeutic target for autoimmune disease, cancer, inflammation and IL-17-associated disease (U.S. Patent No. 8,846,311 B2 and Europe Patent).
(2) MAP4K4/HGK: The kinase MAP4K4 is a diagnostic and drug target for non-obese type 2 diabetes.
(3) DUSP22/JKAP: The phosphatase DUSP22 is a diagnostic/prognostic biomarker and drug target for systemic lupus erythematosus nephritis.
(4) Others: T cell signalling, T cell-mediated diseases.

Interests

- Technology transfer (license out) and Co-development or other partnership
- Targeted companies in Belgium: GSK, Merck

BIONET Corp.

Sub-sectors: Stem Cell, Genetic Testing, Informatics, Precision Medicine

Mr. Chris TSAI, Chairman
Email: chris@babybanks.com

Address: No.28, Ln. 36, Xinhu 1st Rd., Neihu Dist., Taipei City 114, Taiwan
Tel: 886-0800-800 018
Website:
http://www.babybanks.com/

Introduction

BIONET Corp. was established in 1999 as the pioneer company in the field of stem cell applications in Taiwan. BIONET has focused in two areas: "Stem Cell Therapy" and "Genetic Testing". In 2007, BIONET successfully completed initial public offering (IPO) and became the first publicly traded company in the stem cell and genetic testing industry of Taiwan.

BIONET is the first private cord blood bank in Asia to be accredited from the American Association of Blood Banks (AABB). Moreover, BIONET is the first company in the world to receive accreditations in three categories from AABB including Cord Blood (CB), Hematopoietic Progenitor Cells (HPC), and Mesenchymal Stem Cells (MSC).

In 2012, GGA Corp., a subsidiary of BIONET, made its IPO as Taiwan's first public company specialized in both precision medicine and scientific informatics. BIONET is the largest enterprise in the cell therapy and genetic testing industry in Taiwan. In 2014, BIONET applied over 10 years of wound healing study achievement in the anti-aging market by launching an innovative skin care product called **RE.O** Stem-Activating Complex.

Interests

- Co-development or other partnership for stem cell therapy and genetic testing.
- Sourcing for cosmetic distributors and customers

Quark Biosciences

Sub-sectors: Diagnostics, Device, Service

Ms. Tiffany Wang, Sales and Marketing Specialist
Email: tiffanywang@quarkbiosciences.com

Address: 4F-1, No. 6-2, Shengyi Rd., Sec. 2, Shinchu Biomedical Science Park, Zhubei, Hsinchu City 302, Taiwan
Tel: 886-3-659 0898
Website:
http://www.quarkbiosciences.com/

Introduction

By partnering with doctors and researchers worldwide, QuarkBio focuses on developing innovative precision cancer, disease diagnosis, and fertility treatment solutions to be used alongside clinical examinations, improving patients' quality of life without the financial burdens of long-term healthcare.

QuarkBio develops innovative tests, based on the domain knowledge of either in-house staff scientists or outside collaborators with a proprietary platform called PanelChip™. QuarkBio co-develops tests on PanelChip™ platform, creating ready-to-use products to partners for service to end-users. PanelChip™ platform allows scientists to develop unique, novel multi-marker detection tests for precision medicine. PanelChip™ is supported by a system of tools specially designed to assist in biomarker design, reagent kit manufacturing, and bioinformatics, resulting in easy implementation in clinical labs to run customized PanelChip™ applications.

Interests

- Technology transfer (license out)
- Co-development or other partnership for customized applications on PanelChip™

Andros Pharmaceuticals Co., Ltd.

Sub-sectors: Pharma

Dr.Ae-Jun WANG, Chairman

Address: 6F, No. 22, Sec. 2, Shengyi Rd., Zhubei City, Hsinchu County 302, Taiwan
Tel: 886-3-658 1866
Website: http://www.andros.com.tw/index.aspx?lang=en

Introduction

Andros Pharmaceuticals Co., Ltd. is a bio/pharmaceutical company focused on developing innovative drug delivery systems. Using lipid-based technology as platform, the company is currently developing microencapsulated drugs for topical delivery and non-viral gene delivery systems. The business strategy of Andros is to bring together patented drug delivery technologies with a team of experienced scientists to create competitive new dosage forms. In addition, Andros is advancing high-end cosmetic ingredients by pharmaceutical level encapsulation technologies to create profits for the company.

Andros was established on July of 2008 and located in the Industrial Technology Research Institute (ITRI) incubation center. ITRI is the largest applied science institution with advanced resources/equipment and a vigorous research atmosphere that nurtured Andros since its establishment. For future prospects and long term management, the company has relocated to the Hsinchu biomedical science park in 2013 where there will be increased employment opportunities as well as the establishment of a pilot plant that meets PIC/S GMP regulations for the scale up of new dosage forms. The plant will produce samples needed for clinical trials and will shorten product development time in order to achieve earlier market presence globally.

Interests

Technology transfer and co-development or other partnership

PharmaEssentia Corp.

Sub-sectors: Pharma

Dr. Ching-Leou TENG, Chairman

Address: 13F, No.3, YuanQu St.
NanKang District Taipei 115, Taiwan
Tel: 886-2-26557688
Website:
http://www.pharmaessentia.com.tw

Introduction

PharmaEssentia, PEC's leading compound, P1101 (Peg-P-IFN-alpha-2b) is a single predominant (>90%) positional isomer that has better controlled purity as compared to other pegylated interferons. Our partner, AOP Orphan Pharmaceuticals is running a Phase III trial which started enrolling in Sep. 2013 in our lead indication, Polycythemia Vera. Results was read out in 1H15. At ASH 2012, AOP announced promising Phase II data for P1101 with >90% 1 year response rates, decrease in spleen size, sustainable reduction in JAK2 allele burden, as well as a benign side effect profile. P1101 has received Orphan Drug Designation from US and EU for PV. PEC had a successful face-to-face meeting with FDA regarding future steps in the US, where FDA informed PEC about the sufficiency of EU data for US filing.

Interests

Technology transfer and co-development or other partnership

Industrial Technology Research Institute

Sub-sectors: Pharma

Ken HWANG, Division Director

Address: Bldg.53-236, 195,Chung Hsing Rd., Sec. 4 Chutung, Hsinchu 310, Taiwan
Website:
https://www.itri.org.tw/eng

Introduction

At the BDL of ITRI, on top of the development of innovative drugs and medical devices, there's ample room for cross-sector support and cooperation.

Three Center of Excellence(COE):

COE for Diagnostic Products

COE for Drug Development

COE for Combination Products

Moreover, BDL has set up the Rapid Prototyping Service Center to help hasten the reaping of research fruits. The Center accepts outside proposals and helps bring promising products to market. Outside projects that are deemed qualified for the Center's subsidy program will be accorded a considerable capital injection to reduce their costs.

Interests

Technology transfer and co-development or other partnership

Trust Bio-sonics, Inc.

Sub-sectors: Pharma

Winters Fu, Director,Business Development Dept.

Address: Room 103, No. 8, Sec. 2, Shengyi Rd., Zhubei City, Hsinchu County 30261, Taiwan (R.O.C.)
Website:
www.trust-biosonics.com

Introduction

TRUST Bio-sonics, founded in 2013, is a pharmaceutical company focused on drug developments, specializing in the developments of the products related to early diagnosis and treatment of cancers.

Our R & D team includes the experts from the top research institutions of medical imaging and drug delivery.

The core technology is the microbubble-based ultrasound drug delivery system (UDDS), through using focused ultrasound to rupture microbubbles to locally release drug molecules on the targeted region. The UDDS is designed to reduce side effects and increase drug absorption. TRUST further has the strong experiences in liposomal formulations. We aim to integrate both bubble and liposome technologies to offer new treatment solutions.

The pilot production and analysis laboratories have been built in Hsinchu Biomedical Science Park for early developments of new products. For the main product line, TRUST has contracted with a PIC/S GMP-certificated CMO for the followed mass production. Our core vision is to provide patients with early diagnosis and treatment solutions, improving the health status of patients and providing better living quality. " Lead innovations and create values " is the goal of TRUST Bio-sonics.

Interests

Technology transfer and co-development or other partnership

Medigen Biotechnology Corporation

Sub-sectors: Pharma

Dr. Stanley Chang, CEO

Address: 14F, No. 3, Park St., Nangang District, Taipei 11503, Taiwan
Website: http://www.medigen.com.tw/en/home/

Introduction

Medigen Biotechnology Corp. (MBC) was established in late 1999. The company upholds the vision of “Innovations for a better life” focusing on the development of new therapies for liver diseases and cancers. MBC has now gradually developed into a comprehensive biopharmaceutical corporation with business fields covering new drug development, innovative drug discovery, molecular diagnostics, vaccine, and generic drugs.

Interests

Technology transfer and co-development or other partnership

Personal Genomics

Sub-sectors: Biotech

Vera Liu, Manager

Address: 8 Shenyi Rd., Sec. 2, 4F,
Hsinchu Biomedical Science Park,
Zhubei, Hsinchu 30261 Taiwan
Website:

Introduction

Located in Taiwan's Silicon Valley, Hsinchu, Personal Genomics is leveraging Taiwan's strength in advanced IC design and semiconductor manufacturing to develop a world-leading optoelectronic single-molecule sequencing (OES) technology. OES is capable of sequencing millions of DNA molecules with long read-length in real time, thus the cost and time of sequencing can be drastically reduced. The company, aiming to sequence a human-sized genome with much shorter time and lower cost, strives to bring gene sequencing applications to many as yet untapped mass markets.

Interests

Technology transfer and co-development or other partnership

ACT Genomics

Sub-sectors: Diagnostics

Angus Wu, Associate Director

Address: 3F., No.345, Xinhu 2nd Rd., Neihu Dist., Taipei City 114, Taiwan (R.O.C.)
Website:
www.actgenomics.com

Introduction

ACT Genomics, a leading integrated cancer profiling service provider in Asia, brings services to transform treatment paradigm, enhance treatment solution for targeted therapy and immunotherapy, monitor changes in tumor, and support precision oncology drug development in the CAP-accredited environment.

Interests

Technology transfer and co-development or other partnership

General Biologicals Corp. (GBC)

Sub-sectors: Diagnostics

Frank Lin, Vice President

Address: No.6, Innovation First Road Hsinchu Science Park HsinChu 30076, Taiwan
Website:
www.gbc.com.tw

Introduction

General Biologicals Corp. (GBC), founded in 1984, is the industry-leading in-vitro diagnostic device manufacturer in Taiwan. GBC is certified with IVD Class III, GMP and ISO 13485:2003. GBC has developed a wide spectrum of technology platform in various diagnostics products such as Raw Materials (antibody & antigen), Radioimmunoassay (RIA), Enzyme-linked Immunoassay (ELISA), Point-of-Care Test (POCT) and Real-Time Polymerase Chain Reaction (RT-PCR). In addition, GBC has its own intensive sequential vertical technology platform of hybridoma techniques, cell culture, genetic engineering, protein purification and peptide synthesis, assay, coating, fill-in and labeling.

Interests

Technology transfer and co-development or other partnership

TLC

Sub-sectors: Biotech

George Yeh, CEO

Address: 2F, No.3, Yuanqu Street,
Nangang District, Taipei 115, Taiwan
Website:
www.tlcbio.com

Introduction

TLC develops novel nanomedicines that maximize the potential of its proprietary lipid-based technologies and is focused on therapies for the treatment of oncologic and ophthalmologic diseases as well as for the management of acute and chronic pain. TLC's technology is highly scalable and versatile, enabling the design of sustained release and targeted therapies capable of reducing toxicities and improving effectiveness. TLC's advanced programs include TLC388, a first-in-class chemo-radiosensitizer for oncologic indications such as hepatocellular carcinoma and rectal cancer; ProDex, a durable treatment for macular edema secondary to retinal vein occlusion and TLC599, a sustained release treatment for the management of pain associated with osteoarthritis of the knee.

Interests

Technology transfer and co-development or other partnership

PharmaEngine, Inc.

Sub-sectors: Biotech

Johnson Yu, Project Manager

Address: 11F, 10 Sec. 3 Minsheng Road, Taipei 104 Taiwan
Website:
www.pharmaengine.com

Introduction

PharmaEngine, Inc. is a biopharmaceutical company established in February 2003 with funding from TTY Biopharm and Taiwanese venture capital. PharmaEngine is a networked pharma company that operates according to a “No Research, Development Only (NRDO)” model. It is led by Dr. Grace Yeh and supported by a strong network of reputable advisors and consultants worldwide.

PharmaEngine focuses on the development of new drugs for the treatment of cancer and Asian-prevalent diseases. There are 3 projects in the pipeline. ONIVYDEâ(PEP02, MM-398, nal-IRI), a new formulation of an anti-cancer drug for the patients with gemcitabine-treated metastatic pancreatic cancer, was approved by both the US FDA and Taiwan FDA in 2015 and EMA in 2016. PEP503 (NBTXR3), a nanoparticle working as a radio-enhancer, is in a pivotal clinical study in soft tissue sarcoma in Europe and Asia-Pacific countries. PEP06, a new chemical entity (NCE) for cancer treatment, is currently in the lead optimization.

Ipsen S.A., a French company, completed the acquisition of ONIVYDEâ from Merrimack Pharmaceuticals, Inc. for the US market right in April 2017 and became the new license partner of PharmaEngine, Inc. PharmaEngine and Ipsen are now working closely to complete NDA for worldwide approval of ONIVYDEâ in the metastatic pancreatic cancer and also life cycle management of ONIVYDEâ in the clinical studies of other new indications. Meanwhile, PharmaEngine continuously puts the best efforts to move forward the clinical and pre-clinical developments of PEP503 (NBTXR3) and PEP06. Furthermore, PharmaEngine is actively seeking potential new projects to in-license for clinical development and further commercial development.

Interests

Technology transfer and co-development or other partnership

OBI Pharma, Inc..

Sub-sectors: Biotech

Amy Huang, CEO

Address: Ste W1907, 19F, #3, Park St,
Nankang Software Park,
Website:
http://www.obipharma.com

Introduction

BI Pharma, Inc., was founded in 2002. Its focus is on the "Unmet Medical Needs" in challenging diseases throughout the world, such as Cancer. OBI strives to improve health and the quality of life through innovative and cost-effective therapeutics.

OBI's core competence is its R&D expertise in developing novel cancer and infectious disease therapies. The company has an exciting pipeline of products built on a ground-breaking carbohydrate synthesis discovery platform.

The company's flagship product in development is OBI-822, a first-in-class active immunotherapy for metastatic breast cancer. The on-going Phase 2/3 multinational, randomized controlled trial for metastatic breast cancer (ClinicalTrials.gov Identifier: NCT01516307) was launched in 2011. OBI is also devoted to developing next generation active immunotherapies for difficult to treat cancers, including lung, prostate, pancreatic, stomach, and ovarian. The company is the license holder for DIFICID™ in Taiwan and owns the commercial rights to the product, a novel antibiotic indicated for C. difficile-associated diarrhea.

OBI is listed on Taiwan's GreTai Securities Market Exchange as an Emerging Company (Stock code: 4174). It has established wholly-owned subsidiaries in the US and China. The company is led by a management team with a track record of success in new drug development and commercialization.

Interests

Technology transfer and co-development or other partnership